title: Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta-analysis of case-control studies.
abstract: Bladder cancer is a commom malignancy in the urinary tract that is influenced by genetic and environmental factors. The role of functional polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene with bladder cancer risk remains to be determined. This meta-analysis was performed to derive a more precise estimation of MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk. Data were collected with the last report up to September 2013. A total of 3,463 cases and 3,927 controls for Ala222Val, and 3,177 cases and 3,502 controls for Glu429Ala were analyzed. The pooled odds ratios (ORs) and 95% confidence interval (CI) were estimated for the association with bladder cancer risk. Overall, no significant associations of Ala222Val and Glu429Ala polymorphisms with bladder cancer risk were found (for Ala222Val: Val/Val vs. Ala/Ala: OR, 1.02; 95% CI: 0.80-1.29; Val/Ala vs. Ala/Ala: OR, 1.02; 95% CI: 0.92-1.12; dominant model: OR, 1.01; 95% CI: 0.87-1.17; recessive model: OR, 1.00; 95% CI: 0.87-1.15; and for Glu429Ala: Ala/Ala vs. Glu/Glu: OR, 1.11; 95% CI: 0.78-1.58; Ala/Glu vs. Glu/Glu: OR, 1.16; 95% CI: 0.95-1.40; dominant model: OR, 1.15; 95% CI: 0.94-1.41; recessive model: OR, 0.96; 95% CI: 0.79-1.15). In stratified analyses by ethnicity, significant associations were observed for Glu429Ala polymorphism in individuals of Middle Eastern descent (Ala/Glu vs. Glu/Glu: OR, 2.11; 95% CI: 1.26-3.53; dominant model: OR, 2.16; 95% CI: 1.16-4.01; recessive model: OR, 1.82; 95% CI: 1.11-3.01). This meta-analysis demonstrated that overall there was no association of MTHFR Ala222Val and Glu429Ala polymorphisms with bladder cancer risk. However, in the stratified analysis by ethnicity the MTHFR Glu429Ala polymorphism was significantly associated with increased bladder cancer risk in individuals of Middle Eastern descent.
authors.affiliation: Institute of Genetic Engineering, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
authors.forename: Rong
authors.initials: R
authors.lastname: Shi
authors.affiliation: Department of Urinary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Institute of Genetic Engineering, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhou
authors.affiliation: Institute of Genetic Engineering, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
authors.forename: Jueyu
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Urinary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
authors.forename: Wanlong
authors.initials: W
authors.lastname: Tan
keywords: bladder cancer; meta-analysis; methylenetetrahydrofolate reductase; polymorphism
references.citation: Trends Genet. 2004 Sep;20(9):439-44
references.pmid: 15313553
references.citation: Int J Cancer. 2007 Jun 1;120(11):2452-8
references.pmid: 17311259
references.citation: Genet Med. 2002 Mar-Apr;4(2):45-61
references.pmid: 11882781
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Cancer Genet Cytogenet. 2009 Nov;195(1):43-53
references.pmid: 19837268
references.citation: Mutat Res. 2001 Jun;458(1-2):49-54
references.pmid: 11406421
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Cancer Causes Control. 2010 Oct;21(10):1605-13
references.pmid: 20532609
references.citation: Cancer Lett. 2004 Aug 10;211(2):199-207
references.pmid: 15219943
references.citation: Clin Exp Med. 2009 Mar;9(1):9-19
references.pmid: 18815869
references.citation: Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65
references.pmid: 18815930
references.citation: Cancer Sci. 2010 Mar;101(3):782-6
references.pmid: 20002681
references.citation: J Biomed Res. 2013 May;27(3):170-8
references.pmid: 23720672
references.citation: Int J Hyg Environ Health. 2005;208(5):321-7
references.pmid: 16217917
references.citation: World J Urol. 2009 Jun;27(3):289-93
references.pmid: 19219610
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cancer Sci. 2004 Nov;95(11):908-13
references.pmid: 15546509
references.citation: Med Oncol. 2011 Dec;28 Suppl 1:S398-412
references.pmid: 21046286
references.citation: Carcinogenesis. 2004 Sep;25(9):1639-47
references.pmid: 15117811
references.citation: Mol Biol Rep. 2012 Jan;39(1):635-43
references.pmid: 21556759
references.citation: Carcinogenesis. 2004 May;25(5):729-34
references.pmid: 14688016
references.citation: J Nutr. 2003 Nov;133(11 Suppl 1):3748S-3753S
references.pmid: 14608109
references.citation: Nat Genet. 1995 May;10(1):111-3
references.pmid: 7647779
references.citation: Cancer Detect Prev. 2009;32(5-6):395-402
references.pmid: 19588544
references.citation: Cancer Genet Cytogenet. 2007 Jul 1;176(1):48-53
references.pmid: 17574963
references.citation: Mol Genet Metab. 1998 Jul;64(3):169-72
references.pmid: 9719624
references.citation: Biomarkers. 2007 Nov-Dec;12(6):635-44
references.pmid: 17972183
references.citation: J Int Med Res. 2009 Nov-Dec;37(6):1882-9
references.pmid: 20146887